Correction to: The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease
View / Open Files
Authors
Ritchie, Craig W
Russ, Tom C
Banerjee, Sube
Barber, Bob
Boaden, Andrew
Fox, Nick C
Holmes, Clive
Isaacs, Jeremy D
Leroi, Ira
Lovestone, Simon
Norton, Matt
O’Brien, John
Pearson, Jim
Perry, Richard
Pickett, James
Waldman, Adam D
Wong, Wai L
Rossor, Martin N
Burns, Alistair
Publication Date
2018-07-30Publisher
BioMed Central
Type
Article
Metadata
Show full item recordCitation
Ritchie, C. W., Russ, T. C., Banerjee, S., Barber, B., Boaden, A., Fox, N. C., Holmes, C., et al. (2018). Correction to: The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease. https://doi.org/10.1186/s13195-018-0372-0
Abstract
Since the publication of this article [1], it has come to the attention of the authors that information for one of the authors was not included in the competing interests section. Craig Richie has declared potential competing interests with the following companies; Janssen, Eisai, Pfizer, Eli Lilly, Roche Diagnostics, Boeringher Ingleheim, Novartis, AC Immune, Ixico, Aridhia, Amgen, Berry Consultants, Lundbeck, Sanofi, Quintiles (IQVIA) and Takeda. The full competing interests section for this article can be found below.
Identifiers
External DOI: https://doi.org/10.1186/s13195-018-0372-0
This record's URL: https://www.repository.cam.ac.uk/handle/1810/278555
Rights
Rights Holder: The Author(s).